GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT06602453
- Locations
- 🇺🇸
Yale School of Medicine Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸CHI Health Nebraska Heart, Lincoln, Nebraska, United States
🇺🇸James A Haley Veteran Affairs Medical Center - NAVREF - PPDS, Tampa, Florida, United States
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease
- Conditions
- Non Cystic Fibrosis BronchiectasisChronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT06603246
- Locations
- 🇺🇸
Accel Research Site - Achieve - Birmingham - ERN - PPDS, Vestavia Hills, Alabama, United States
🇺🇸TTS Research, Boerne, Texas, United States
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: cBTKi Monotherapy
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06524375
- Locations
- 🇺🇸
Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center, Boston, Massachusetts, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT06488716
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇨🇦Sir Mortimer B Davis Jewish General Hospital-3755 Cote Sainte-Catherine, Montreal, Quebec, Canada
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT06462118
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
🇺🇸Covance Research Unit - Dallas, Dallas, Texas, United States
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
- Conditions
- Refractory CancerRecurrent CancerSolid Tumor, Adult
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06372574
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT06137183
- Locations
- 🇮🇱
Sheba Medical Center - PPDS, Ramat Gan, Israel
🇺🇸Gulf Coast Gatroenterology, Fairhope, Alabama, United States
🇧🇷Pesquisare Saude, Santo Andre, São Paulo, Brazil
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06096779
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Southern California-Keck School of Medicine -1975 Zonal Ave, Los Angeles, California, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced Solid TumorsRecurrent Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06031441
- Locations
- 🇦🇺
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
🇨🇦British Columbia Cancer Agency - 600 10th Ave W, Vancouver, British Columbia, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
- Conditions
- Adenocarcinoma, Pancreatic Ductal
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05968326
- Locations
- 🇰🇷
Severance Hospital - Yonsei Cancer Center, Seoul, Korea, Republic of
🇰🇷University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC), Songpa-gu, Korea, Republic of
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States